Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
BASEL, Switzerland – 15th November 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient has [...]